Latest

27
Sep
Milestone Payments in Pharma & Biotech Licensing Deals

Milestone Payments in Pharma & Biotech Licensing Deals

Overview Milestone payments are contingent fees in pharmaceutical and biotech deals that become due when a product achieves specific goals.
14 min read
26
Sep
Company of the week: Revolution Medicines

Company of the week: Revolution Medicines

Introduction and Company Overview Revolution Medicines (NASDAQ: RVMD) is a late-stage oncology biotech focused on targeting the RAS oncogene family,
39 min read
25
Sep
Fund of the week: Breakout Ventures

Fund of the week: Breakout Ventures

Executive Summary Breakout Ventures is a San Francisco-based venture capital firm specializing in life sciences and "deep tech"
21 min read
24
Sep
Biotech Venture Debt: Technical Analysis of Deal Structuring and Covenant Architecture

Biotech Venture Debt: Technical Analysis of Deal Structuring and Covenant Architecture

Current Market Dynamics and Transaction Volume The biotech venture debt market underwent substantial transformation following the Silicon Valley Bank collapse
7 min read
23
Sep
PIPEs in Biopharma: A 2025 Deep Dive

PIPEs in Biopharma: A 2025 Deep Dive

The biopharma sector in 2025 is navigating a difficult funding landscape. Public markets have cooled off after the boom of
17 min read
22
Sep
Disease-Linked Bonds: Cancer Bonds and Pandemic Bonds – A Comprehensive Analysis

Disease-Linked Bonds: Cancer Bonds and Pandemic Bonds – A Comprehensive Analysis

1. Historical Examples of Disease-Linked Bonds Pandemic Bonds (World Bank PEF) The most prominent example is the World Bank'
42 min read
21
Sep
The weekly term sheet (38)

The weekly term sheet (38)

The week of September 15-20, 2025 witnessed over 40 distinct biotech pharmaceutical transactions totaling more than $6 billion in disclosed
10 min read
20
Sep
The Great AI Wrapper Charade in Biotech

The Great AI Wrapper Charade in Biotech

In boardrooms and biotech conferences alike, one phrase has become inescapable: “our AI-powered platform.” Startups in drug discovery, clinical decision
11 min read
19
Sep
Company of the week: Poxel SA: Navigating Judicial Reorganization While Clinical Assets Retain Promise

Company of the week: Poxel SA: Navigating Judicial Reorganization While Clinical Assets Retain Promise

Poxel SA, a French biopharmaceutical company that successfully developed and commercialized the first-in-class diabetes drug TWYMEEG® in Japan, filed for
12 min read
18
Sep
Fund of the week: OrbiMed Royalty & Credit Opportunities

Fund of the week: OrbiMed Royalty & Credit Opportunities

Executive Summary OrbiMed's Royalty & Credit Opportunities strategy has emerged as a prominent non-dilutive financing platform in the
25 min read